News for Crinetics Pharmaceuticals, Inc. (CRNX)

Operator: Good afternoon, everyone. Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call.

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsGayathri Diwakar -...

Crinetics Pharmaceuticals Inc (CRNX) is a clinical-stage pharmaceutical company with a focus on endocrine diseases and tumors.Despite a strong pipeline and inn

Feb 27, 2025 / 09:30PM GMTOperator Stand by. We're about to begin. Good afternoon everyone. Welcome to the Crinetics Pharmaceuticals fourth quarter and full yea

Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company specializing in novel therapeutics for endocrine diseases, has announced its finan

Net Loss: $80.6 million for Q4 2024, compared to $60.1 million in Q4 2023.EPS: Reported at -$0.88, matching the estimated EPS of -$0.88.Revenue: No revenue rep

Crinetics Pharmaceuticals Inc (CRNX) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $0.72 million, and th

Summary Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company focused on endocrine diseases, announced on February 24, 2025, the appoint

**media[548601]**

Summary Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company specializing in endocrine disease therapeutics, announced on February 20,

**media[546119]**

On December 31, 2024, MPM BIOIMPACT LLC (Trades, Portfolio)executed a significant transaction involving Compass Therapeutics Inc. The firm added 2,926,002 shar

Overview of the Recent Transaction On December 31, 2024, Ikarian Capital, LLC (Trades, Portfolio) made a strategic move by acquiring 967,867 shares of Alpha Cog

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently expanded its holdings in Eton Pharmaceuticals Inc by acquiring an additional 583,3

Overview of StemPoint Capital LP (Trades, Portfolio)'s Recent Transaction On December 31, 2024, StemPoint Capital LP (Trades, Portfolio) executed a strategic tr

On December 31, 2024, StemPoint Capital LP (Trades, Portfolio) executed a noteworthy transaction by acquiring an additional 481,700 shares of Vistagen Therapeut

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic decision to reduce its holdings in Atea Pharmaceuticals Inc (AVIR

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Aadi Bioscience Inc. On December 31,

On December 31, 2024, Driehaus Capital Management LLC made a significant move by acquiring an additional 340,410 shares of Korro Bio Inc at a price of $38.07 pe